Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on developing light-activated compounds for medical applications. Key strengths include a solid gross margin of 52.1% and a very healthy liquidity position, with a current ratio of 5.48. However, the company faces significant concerns with negative EBITDA and net margins, indicating ongoing financial challenges. The high gross margin juxtaposed with low valuation suggests potential but raises questions about profitability and market confidence. Overall, while liquidity is strong, the path to profitability remains uncertain.
Loading financial metrics...
Revenue fell 24.9% year-over-year from $1.1M to $802K. The decline has persisted for multiple quarters.
Company posted a loss of $-3.8M over the last year, representing 472.5% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.4M over the last year.
Strong gross margin of 57.9% reflects healthy unit economics.
Fortress balance sheet: cash covers total debt 35×, providing significant financial flexibility.
Excellent liquidity with current ratio of 5.5x ensures operational stability.
Low debt-to-revenue ratio of 18.5% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Based on 2026-Q2 (June 30, 2026)